Alex Sigal

This study finds low neutralizing antibody prevalence to GRAd32 in southern African populations, suggesting its potential as an HIV vaccine vector despite prior Ad26 vaccination.

This study investigates the B-cell response to transient HIV viraemia in elite controllers, revealing TLM heterogeneity and the role of innate-like B cells.

The paper assesses the virulence of the SARS-CoV-2 BA.2.86 variant in hamsters and finds it is attenuated compared to BA.2.75.

The paper compares SARS-CoV-2 antigenicity across assays and in human and animal model sera, finding similar immunodominance patterns and antigenic maps but differences in titer magnitude and assay-specific fold change.

The paper investigates the origin of HIV in the CNS of ART-suppressed individuals and finds T cell-derived HIV that can lead to drug resistance.

The paper develops a mathematical model to predict HIV infection clearance with PrEP, showing that reducing infection frequency per cell is more effective than reducing viral burst size.

This study shows HIV-1 evades apoptosis in macrophages by manipulating the MAP2K1/ERK2 pathway to dysregulate lincRNA-p21, and suggests MAP2K1/ERK2 inhibitors as a therapeutic strategy.

The paper shows that partial inhibition of HIV transmission can increase live infected lymph node cells by reducing cell death, even with fewer HIV DNA copies per cell.